Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. September 2014 07:36 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

CARMIEL, Israel, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Yossi Maimon, the Company's Chief Financial Officer, will present at...
28. August 2014 17:50 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs

CARMIEL, Israel, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it will host a conference call on Wednesday, September 3, 2014 at...
24. Juli 2014 08:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors

CARMIEL, Israel, July 24, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it has chosen Mr. Shlomo Yanai as Chairman of the Company's Board of...
27. Juni 2014 07:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

CARMIEL, Israel, June 27, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSOTM (taliglucerase alfa) will be presented...
23. Juni 2014 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces New Data on ELELYSO(TM) (taliglucerase alfa) and Oral GCD to be Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

CARMIEL, Israel, June 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSO™ and oral glucocerebrosidase (GCD),...
18. Juni 2014 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease

CARMIEL, Israel, June 18, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first Gaucher patient has been enrolled in the Company's phase IIa...
13. Juni 2014 08:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year

CARMIEL, Israel, June 13, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today, that David Aviezer, Ph.D., has decided to retire after almost 12 years...
30. Mai 2014 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients

CARMIEL, Israel, May 30, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Health Canada has granted regulatory approval to ELELYSO™...
28. Mai 2014 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

CARMIEL, Israel, May 28, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that senior management will present at the Jefferies 2014 Global Healthcare...
22. Mai 2014 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients

CARMIEL, Israel, May 22, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Australian Therapeutic Goods Administration (TGA) has granted...

Vorherige Seite